Vertex Pharmaceuticals Inc (VRTX)
484.53
-0.29
(-0.06%)
USD |
NASDAQ |
Apr 01, 15:54
Vertex Pharmaceuticals Enterprise Value: 118.38B for March 31, 2025
View 4,000+ Financial Data Types:
Add
Browse
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences Inc | 154.60B |
| Eli Lilly and Co | 772.11B |
| Moderna Inc | 3.936B |
| Biogen Inc | 23.95B |
| AbbVie Inc | 431.51B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 913.00M |
| Revenue (Quarterly) | 2.912B |
| Total Expenses (Quarterly) | 1.800B |
| EPS Diluted (Quarterly) | 3.50 |
| Gross Profit Margin (Quarterly) | 85.46% |
| Profit Margin (Quarterly) | 31.35% |
| Earnings Yield | -0.45% |
| Operating Earnings Yield | 3.50% |
| Normalized Earnings Yield | 2.475 |